Stocks and InvestingStocks and Investing
Tue, May 21, 2024
Mon, May 20, 2024
Fri, May 17, 2024

Joel Beatty Downgraded (BMRN) to Hold and Decreased Target to $72 on, May 17th, 2024


Published on 2024-10-28 11:28:42 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Baird, Downgraded "BioMarin Pharmaceutical Inc." (BMRN) to Hold and Decreased Target from $104 to $72 on, May 17th, 2024.

Joel has made no other calls on BMRN in the last 4 months.



There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 4 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $89 on, Friday, April 26th, 2024
  • David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024
  • George Farmer of "Scotiabank" Maintained at Hold with Increased Target to $85 on, Thursday, April 25th, 2024
  • Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Friday, February 23rd, 2024


These are the ratings of the 5 analyists that currently disagree with Joel


  • Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $113 on, Tuesday, May 14th, 2024
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, April 26th, 2024
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $110 on, Thursday, April 25th, 2024
  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Thursday, April 25th, 2024
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $107 on, Friday, February 23rd, 2024